Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Deutsche Bank German & Austrian Corporate Conference 2012

25 slides from Fresenius SE & Co. KGaA's conference presentation, May 15, 2012

  1. Slide 1: Deutsche Bank German & Austrian Corporate Conference

    Deutsche Bank German & Austrian Corporate Conference May 15, 2012

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Achieving Profitable Growth in Attractive Health Care Segments

    Achieving Profitable Growth in Attractive Health Care Segments Frankfurt listing (DAX30): FRE 100% Fresenius US ADR program (OTC): FSNUY Biotech Sales 2011: €16.5 bn EBIT 2011: €2,563 m Oncology and Immunology Therapies EBIT 2011: -€30 m 31% 100% 100% 77% Fresenius Fresenius Fresenius Fresenius Medi

  4. Slide 4: Fresenius Group: Financial Results

    Fresenius Group: Financial Results €m 15,972 16,522 Sales 5-year CAGR: 10% 14,164 +6% cc 12,336 2,563 EBIT 11,358 2,418 5-year CAGR: 12% +9% cc 2,054 1,727 770 Net Income 1,609 5-year CAGR: 17% 660 +18% cc 514 450 410 2007 2008 2009 2010 2011 Group financial results before APP-transaction-related sp

  5. Slide 5: Fresenius Share: Attractive Long-Term Shareholder Returns

    Fresenius Share: Attractive Long-Term Shareholder Returns 19th consecutive dividend increase Compounded annual total return 2011 proposal: +10%; €0.95 per share 2002 – 2011 € 0.95 0.86 Fresenius 12.2% p.a. 0.75 share 0.70 0.66 0.57 0.49 0.45 0.41 0.38 DAX30 1.4% p.a. 0.07 1 '93 '02 '03 '04 '05 '06 '

  6. Slide 6: Fresenius Group: Financial Results

    Fresenius Group: Financial Results Sales1 EBIT Net income2 Q1/12 €4,419 m €661 m €200 m Growth at constant 10% 12% 15% currency rates Growth at actual 13% 15% 18% currency rates 1 Previous year’s sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care 2 Net income at

  7. Slide 7: Fresenius Group: Financial Results by Business Segment

    Fresenius Group: Financial Results by Business Segment Q1/12 Fresenius Fresenius Fresenius Fresenius Medical Care Kabi Helios Vamed Sales US$3,249 m €1,092 m €717 m €142 m Growth 9% 14% 11% 1% EBIT US$503 m €215 m €68 m €5 m Growth 13% 9% 17% 0% Deutsche Bank German & Austrian Corporate Conference,

  8. Slide 8: Fresenius Kabi: Update Q1/12

    Fresenius Kabi: Update Q1/12 - 11% organic sales growth, all regions at Strong Organic Growth in All Regions or above expectations - North America – strong growth continues Europe 8% due to 2011 launches (e.g. PipTazo, Nafcillin) and persisting drug shortages North 10% America - 16% organic sales gr

  9. Slide 9: Fresenius Helios: Update Q1/12

    Fresenius Helios: Update Q1/12 - 5% organic sales growth – at upper end of Damp Acute Care Hospital Kiel guidance, 4% increase in admissions - Excellent margin development across all hospitals in established business – 170 bps EBIT margin increase to 10.7% - Damp acquisition consolidated as of March

  10. Slide 10: Fresenius Vamed: Update Q1/12

    Fresenius Vamed: Update Q1/12 - Sales and EBIT in line with expectations Largest service business contract – University Hospital AKH Vienna - 16% sales growth in service business – broad portfolio of ~150 multi-year service contracts supports long-term growth - Order intake in project business parti

  11. Slide 11: Group: Financial Outlook by Business Segment Fully Confirmed or Raised

    Fresenius Group: Financial Outlook by Business Segment Fully Confirmed or Raised Previous New Fresenius Sales growth1 4% – 6% 6% – 8% Kabi EBIT margin 19.5% – 20% upper end of range Fresenius Sales growth1 3% – 5% confirmed Helios EBIT €310 m – €320 m upper end of range Fresenius Sales growth 5% – 1

  12. Slide 12: Group: Financial Outlook Raised

    Fresenius Group: Financial Outlook Raised Previous New Revenue growth1 10% – 13% upper end of range at constant currency Net income growth2 8% – 11% 12% – 15% at constant currency Capex ~5% of Group sales confirmed 1 Previous year’s sales were adjusted according to a U.S. GAAP accounting change at F

  13. Slide 13: Attachments

    Attachments Untertitel der Kapiteltrennseite Maximal zweizeilig, 18 pt Deutsche Bank German & Austrian Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, May 15, 2012 Page 13

  14. Slide 14: Fresenius Group: Profit and Loss Statement

    Fresenius Group: Profit and Loss Statement €m Q1/12 Q1/11 Growth Q1/12 YoY actual constant rates rates Sales1 4,419 3,923 13% 10% EBIT 661 575 15% 12% Net interest -147 -135 -9% -6% Income taxes -156 -135 -16% -13% Net income2 200 170 18% 15% 1 Previous year’s sales were adjusted according to a U.S.

  15. Slide 15: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow €m Q1/12 LTM Q1/11 LTM Growth Margin1 Margin1 YoY Operating Cash Flow 538 11.6% 278 10.8% 94% Capex (net) -152 -4.6% -147 -4.6% -3% Free Cash Flow 386 7.0% 131 6.2% 195% (before acquisitions and dividends) Acquisitions (net) -1,458 -249 -- Dividends -24 -15 -60% Free Cash

  16. Slide 16: Cash Flow Development

    Cash Flow Development €m Operating CF Capex (net) Free Cash Flow1 Q1/12 LTM Margin Q1/12 LTM Margin Q1/12 LTM Margin 93 11.9% (36) (4.0%) 57 7.9% 34 9.5% (19) (5.8%) 15 3.7%3 45 -8.7% (1) (0.8%) 44 -9.5% Corporate/ Other -1 n/a (3) n/a -4 n/a excl. FMC 171 9.6% 2 (59) (4.5%) 112 5.1% 2 Group 538 11.

  17. Slide 17: Fresenius Group: Debt and Interest Ratios

    Fresenius Group: Debt and Interest Ratios Mar 31, Dec 31, Net debt/EBITDA 2012 2011 Target2 2012YE: Debt (€m) 11,459 9,799 3.51 3.50 3.46 ≤3.0 thereof 54% US$ denominated 3.28 Net debt (€m) 10,604 9,164 3.07 2.95 2.95 Net debt/EBITDA 3.011 2.83 2.92 2.71 2.75 2.632.63 2.72 EBITDA/Interest 5.7 6.1 2.

  18. Slide 18: Fresenius Kabi: Strong Organic Sales Growth

    Fresenius Kabi: Strong Organic Sales Growth €m Q1/12 Q1/11 Organic Growth Infusion Therapy 246 220 10% I.V. Drugs 410 355 12% Clinical Nutrition 316 270 14% Medical Devices/ Transfusion Technology 120 115 4% Total sales 1,092 960 11% Deutsche Bank German & Austrian Corporate Conference, Fresenius SE

  19. Slide 19: Fresenius Kabi: Strong Organic Sales Growth

    Fresenius Kabi: Strong Organic Sales Growth €m Q1/12 Q1/11 Organic Growth Europe 487 449 8% North America 292 254 10% Asia-Pacific 199 156 20% Latin America/Africa 114 101 15% Total sales 1,092 960 11% Deutsche Bank German & Austrian Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations

  20. Slide 20: Fresenius Kabi: Excellent EBIT Improvement

    Fresenius Kabi: Excellent EBIT Improvement €m Q1/12 Q1/11 Growth Europe 96 95 1% Margin 19.7% 21.2% North America 114 96 19% Margin 39.0% 37.8% Asia-Pacific/Latin America/Africa 58 42 38% Margin 18.5% 16.3% Corporate and Corporate R&D -53 -36 -47% Total EBIT 215 197 9% Margin 19.7% 20.5% Deutsche Ba

  21. Slide 21: Fresenius Helios: Strong Sales and EBIT Growth

    Fresenius Helios: Strong Sales and EBIT Growth €m Q1/12 Q1/11 Growth Total sales 717 648 11% EBIT Established clinic portfolio 72 58 24% Margin 10.7% 9.0% Acquisitions -4 (consolidation <1 yr) Total EBIT 68 58 17% Margin 9.5% 9.0% Deutsche Bank German & Austrian Corporate Conference, Fresenius SE &

  22. Slide 22: Fresenius Helios: Performance Indicators

    Fresenius Helios: Performance Indicators Q1/12 Q1/11 Change No. of hospitals1 75 65 15% - Acute care clinics 51 45 13% - Post-acute care clinics 24 20 20% No. of beds1 23,606 3 20,112 17% - Acute care clinics 18,804 16,690 13% - Post-acute care clinics 4,802 3,422 40% Admissions2 - Acute care (inpat

  23. Slide 23: Fresenius Vamed: Sales Growth and EBIT in line with Expectations

    Fresenius Vamed: Sales Growth and EBIT in line with Expectations €m Q1/12 Q1/11 Growth Project business 77 84 -8% Service business 65 56 16% Total sales 142 140 1% Total EBIT 5 5 0% Margin 3.5% 3.6% Order intake1 104 127 -18% 2 Order backlog1 872 845 3% 1 Project business only 2 Dec 31, 2011 Deutsch

  24. Slide 24: Share Information

    Share Information Share key facts Number of shares1 163,334,670 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTC-market Structure

  25. Slide 25: Financial Calendar

    Financial Calendar 12.06.2012 Capital Market Day Fresenius Kabi 01.08.2012 Report on 1st half 2012 31.10.2012 Report on 1st – 3rd quarter 2012 Contact Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected] For further information a

Fresenius SE & Co. KGaA — Deutsche Bank German & Austrian Corporate Conference 2012 on 6ix